Study of Denufosol (INS37217) in Subjects With Rhegmatogenous Retinal Detachment
NCT00083967
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
23
Enrollment
INDUSTRY
Sponsor class
Conditions
Retinal Detachment
Interventions
DRUG:
denufosol tetrasodium (INS37217) Intravitreal Injection
Sponsor
Merck Sharp & Dohme LLC